Management of drug resistant tuberculosis: isoniazid resistant, rifampicin resistant, multi drug resistant, and extensively drug resistant

Mycobacterium tuberculosis strains that are resistant to an elevating number of second-line medicines used treat multidrug-resistant becoming a threat public health worldwide. Recent guidelines recommended at least 20 months treatment, but recent regimens toxic, poorly tolerated and insufficiently effective, with cure rates as low 36% failure high 50%. The emergence can be defined isoniazid rifampin has introduced they challenging, overcome the complexities programs have responded by treating drugs. Longer treatments for rifampicin or which last 18 more according new 2019 updated World Health Organization drug-resistant may standardized individualized. usually designed involve minimum considered effective based on patient history drug-resistance patterns. exact drugs extensively is unknown, most individuals will receive five six Identically, majority patients been previously treated tuberculosis, prior exposure like ethionamide terizidone frequently excludes their use.